SECURI	TIES AND EXCHANGE COMM	IISSION
	Washington, D.C. 20549	
	FORM 8-K	
	CURRENT REPORT	
	PURSUANT TO SECTION 13 OR 15(d) OF THE	
	SECURITIES EXCHANGE ACT OF 1934	
D	rate of Report (Date of Earliest Event Reported): June 22, 2004	4
ANTARES PHARMA, INC.		
	(Exact Name of Registrant as Specified in Charter)	
Minnesota (State or Other Jurisdiction of Incorporation)	0-20945 (Commission File Number)	41-1350192 (I.R.S. Employer Identification No.)
707 Eagleview Boulevard, Suite 414, Exton, PA 19341		

(Address of Principal Executive Offices) (Zip Code)

# Edgar Filing: ANTARES PHARMA INC - Form 8-K

Registrant s telephone number, including area code: (610) 458-6200

## Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

## Edgar Filing: ANTARES PHARMA INC - Form 8-K

#### Item 9. Regulation FD Disclosure.

Antares Pharma, Inc. (the Company ) today made a presentation at its Annual Meeting of Shareholders regarding its operations and business. The PowerPoint slide presentation used during the Company s presentation at its Annual Meeting of Shareholders is furnished as Exhibit 99.1

The information in this Item 9 and Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended.

### Item 7. Financial Statements and Exhibits.

- (c) Exhibits.
  - 99.1 PowerPoint Slides (furnished)

## Edgar Filing: ANTARES PHARMA INC - Form 8-K

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 22, 2004 ANTARES PHARMA, INC.

By /s/ Lawrence M. Christian

Lawrence M. Christian Chief Financial Officer